It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Inicio> Publicaciones

Estudios de fase III

Datos de la semana 96 de los ensayos HAWK y HARRIER

Dugel PU, Singh RP, Koh A, Ogura Y, Weissgerber G, et al. HAWK and HARRIER: 96-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-related Macular Degeneration. Ophthalmology 2020; in press.

Datos de la semana 48 de los ensayos HAWK y HARRIER

Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, et al. HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology 2020;127:72–84.

Estudios de fase II

Estudio OSPREY

Dugel PU, Jaffe GJ, Sallstig P, Warburton J, Weichselberger A, et al. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial. Ophthalmology 2017;124:1296–304.

Estudio SEE

Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, et al. Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. Ophthalmology 2016;123:1080–9.

Informes del Comité de Revisión de Seguridad

Informe preliminar

Safety Review Committee. Novartis-Appointed Safety Review Committee Reports Initial Brolucizumab Findings. Published June 2020

Revisión post hoc de HAWK y HARRIER

Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, et al. Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER. Ophthalmology 2020; en prensa